ArticleJournal of ovarian research2026
Impact of oral contraceptive treatment duration on ovarian reserve markers and pain in women with ovarian endometrioma: a retrospective cohort study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral contraceptive pills (OCPs) are widely used for symptom control in women with ovarian endometrioma; however, their impact on ovarian reserve and the optimal duration of treatment remain uncertain, particularly for women planning future fertility.
objectiveTo evaluate the association between oral contraceptive pill (OCP) treatment duration and ovarian reserve markers, pain scores, and endometrioma size in women with ovarian endometrioma.
methodsThis retrospective cohort study included 210 reproductive-aged women diagnosed with ovarian endometrioma between August 2018 and August 2025. Women were grouped according to OCP use as part of routine clinical management: Group A (no OCP, n = 112) and Group B (OCP use for 3–6 months, n = 98). Ovarian reserve markers [anti-Müllerian hormone (AMH) and antral follicle count (AFC)], endometrioma size, and pain scores assessed by visual analogue scale (VAS) were compared between groups at baseline, 3 months, and 6 months. Within-group comparisons between 3 and 6 months were also performed among OCP users.
resultsBaseline demographic and clinical characteristics were comparable between groups. At 3 months, OCP users showed significantly lower VAS pain scores compared with non-users (p = 0.032), while ovarian reserve markers were significantly lower in the OCP group [AMH (p = 0.043) and AFC (p = 0.022)]. At 6 months, endometrioma size (p = 0.048) and pain scores (p = 0.012) remained significantly lower in the OCP group. AMH (p = 0.021) and AFC (p = 0.011) also remained significantly lower among OCP users. No significant differences were observed between 3- and 6-month measurements within the OCP group for any outcome.
conclusionIn women with ovarian endometrioma, oral contraceptive use was associated with improvements in pain and reduction in cyst size, accompanied by lower ovarian reserve marker levels during treatment, likely reflecting pharmacologic suppression. Extending OCP treatment beyond three months was not associated with additional clinical benefits, highlighting the importance of individualized treatment duration, particularly for women planning future fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.